with developing and maintaining CTIS. The platform supports every stage of the clinical trial lifecycle—from submission and assessment to supervision and public access to trial information. It allows a single application to cover multiple countries and ensures consistent application of ethical and regulatory requirements.

Key Features and Modules of CTIS

1. Single Dossier Submission for Multiple Member States

CTIS allows sponsors to submit a single dossier, enabling simultaneous assessment by multiple Member States. The dossier includes:

• Part I: General scientific documents applicable across all countries (e.g., protocol, IB).
• Part II: Country-specific documents (e.g., informed consent forms, investigator CVs).

This unified approach minimizes redundancy and ensures consistent evaluations.

2. Role-Based Access and Regulatory Communication

CTIS provides different user roles, including:

• High-level Administrator: Controls organization-wide settings.
• CTIS Administrator: Assigns roles within the organization.
• Clinical Trial Submitters: Prepare and submit dossiers.
• Viewer Roles: Access documents and communications for review.

CTIS includes a secure communication module for formal interactions between sponsors and regulatory authorities during and after the evaluation process.

3. Integrated Timelines and Assessment Procedures

The CTR stipulates precise timelines for assessment:

• Validation of the application: within 10 days.
• Part I assessment: up to 45 days (with optional clock-stops).
• Part II assessment (country-specific): also up to 45 days.

CTIS automatically tracks these timelines, triggers notifications, and stores correspondence to ensure regulatory compliance.

4. Transparency and Public Access

One of CTIS’s core objectives is to enhance clinical trial transparency. All trial-related information—except commercially confidential data—is made publicly available after defined milestones. Sponsors must prepare redacted versions of documents accordingly.

5. Monitoring, Safety Reporting, and Trial Lifecycle Management

CTIS enables:

• Submission of Substantial Modifications (SMs).
• Uploading annual safety reports (ASRs).
• Notifications of start, end, or temporary halt of trials.
• Final study results and layperson summaries.

All interactions are stored with timestamps, creating an audit trail and version control for traceability.

Best Practices for CTIS Use

• Start with organization registration and role assignments via EMA’s Organization Management System (OMS).
• Ensure early preparation of redacted documents for public transparency.
• Use the CTIS Training Environment (sandbox) to familiarize teams with the interface.
• Establish internal workflows to meet CTIS timeline obligations.
• Designate CTIS specialists within your regulatory and clinical operations teams.

Scientific & Regulatory References

• EU Regulation (CTR) No. 536/2014
• EMA CTIS Portal: https://www.ctis.ema.europa.eu
• ICH E6(R2) – GCP Guidelines
• EMA CTIS User Handbook and FAQs
• EMA CTIS Training Modules and Webinars

Special Considerations

Sponsors conducting multinational trials must align document versions and manage translations carefully for Part II submissions. Also, legal representatives are required for non-EU sponsors to access CTIS and conduct regulatory interactions. Ethics Committees still operate under national law, but their assessments are logged within the CTIS framework.

When Sponsors Should Engage with CTIS

• For all new trials initiated after 31 January 2023 (mandatory use).
• When transitioning a trial from Directive 2001/20/EC to CTR 536/2014.
• When submitting substantial modifications or safety updates.
• For uploading lay summaries and final trial results.
• To meet sponsor transparency obligations under EU law.

FAQs

1. Is CTIS mandatory for all EU clinical trials?

Yes. As of 31 January 2023, all new clinical trials in the EU must be submitted via CTIS. Trials approved under the old directive must transition to CTIS by January 2025.

2. Can non-EU sponsors access CTIS?

Yes, but they must designate an EU legal representative to access the system and submit applications on their behalf.

3. What documents are submitted in CTIS?

Documents include the protocol, IB, IMPD, informed consent forms, CVs, insurance certificates, and public redacted versions of required materials.

4. What are clock-stops in CTIS timelines?

Clock-stops allow sponsors to respond to Requests for Information (RFIs) during assessment. The clock pauses until the sponsor submits a response, ensuring accurate tracking of review time.

5. How is transparency managed in CTIS?

CTIS mandates public disclosure of trial-related data. Sponsors must submit both full and redacted versions of certain documents, with redaction guided by EMA’s confidentiality rules.

6. What are Substantial Modifications (SMs) in CTIS?

SMs are major changes requiring regulatory assessment (e.g., protocol changes, dosage alterations). These are submitted and tracked through CTIS and assessed by concerned Member States.

7. Can CROs act on behalf of sponsors in CTIS?

Yes. CROs can be assigned roles within CTIS to prepare and manage submissions if delegated by the sponsor.

Conclusion

CTIS marks a paradigm shift in how clinical trials are managed and authorized in the EU. It improves regulatory efficiency, reduces duplication, and brings a higher standard of transparency and traceability to clinical development. For sponsors and CROs alike, mastering CTIS is not just a compliance requirement—it is a strategic advantage in navigating EU’s complex but harmonized regulatory landscape.